



PRESS RELEASE

AVIOR TO PARTICIPATE AT THE LIVE FORUM: INVEST IN CURES (A Disease Foundation Forum) on FEBRUARY 24, 2022, 9AM – 1PM EST

CARY, N.C., Feb 22, 2022 – Dr. Niraj Vasisht, President and CEO, Avior Bio Inc. will participate in a panel discussion on the “[Innovation in Rare Disease](#)” with four other North Carolina-based company founders who are working in the rare disease space to learn about their science, milestones and path to commercialization in Session 2 from 10:00am - 10:40am, February 24, 2022. The session is moderated by Dr. Christy Shaffer, General Partner, Hatteras Ventures Partners.

Investors interested in a one-on-one meeting with Avior should contact Dr. Vasisht at 919.234.0068.

Avior Bio

Avior Bio is a clinical-stage, pharmaceutical company advancing therapies for the treatment of pruritus (itch) and inflammatory skin disease in rare diseases. Our lead product – AV104 buccal film – is the first-in-kind, dual-action, liver safety product to treat pruritus in primary biliary cholangitis (PBC). PBC is a rare disease.

We have a simple story. Developing drugs from liver disease poses unique challenges. Avior bring two innovative solutions. First, our drug - AV104 - has a dual-action – it blocks the neuropeptide that transmits the itch response and inhibits the inflammatory cytokines that otherwise cause skin inflammation. Second, Avior uses its transmucosal delivery technology - to bypass the impaired liver.

Avior recently completed non-clinical studies and two Phase I studies demonstrating superlative performance and enabling our Phase II clinical program. We are exploring Series A funding for up to \$24M to complete our NDA submissions with multiple, milestones-dependent inflection points. For further information about Avior Bio Incorporated, visit their website at www.AviorBio.com

Invest in Cures

Invest in Cures explores how disease foundations and social venture funds are accelerating the commercialization of early-stage technologies and therapies. [LaunchBio](#) and [the North Carolina Biotech Center](#) welcome researchers, advocates and investment professionals from leading disease foundations that have successfully partnered with local startups focused on oncology and rare disease.